Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Clarient ( CLRT) was the next biggest gainer within the Russell 2000, rising 38.7% in the Oct. 18-Oct. 22 timeframe to close the week at $4.97.

Again, a healthy premium in an acquisition was the driver as General Electric ( GE) anted up for the Aliso Viejo, Calif.-based provider of cancer testing services on Friday, agreeing to buy Clarient for $580 million, or roughly $5 per share, in cash.

Prior to the offer arriving from GE, Clarient shares had been up a little less than 10% year-to-date. The company's third-quarter results are still on tap for Nov. 1 with the average estimate of analysts polled by Thomson Reuters calling for earnings of a penny a share on revenue of $29.3 million.

Clarient will be part of GE Healthcare when the deal is completed in either late 2010 or early 2011, said GE, whose shares are up a little more than 6% year-to-date. In its press release disclosing the Clarient deal, GE said it expects it can build a $1 billion-plus business for diagnostic services, including oncology and other areas.

If you liked this article you might like

Human BioArmor for Your Portfolio

Human BioArmor for Your Portfolio

Futures Mixed on Narrow Citigroup Beat

Futures Mixed on Narrow Citigroup Beat

St. Jude to Acquire AGA Medical

St. Jude to Acquire AGA Medical

Citi's Primerica IPO Points to Strategy Shift

Citi's Primerica IPO Points to Strategy Shift